Fig. 7.

Evaluation of the antimetastatic ability and safety of t-ML@DGLA/siDECR1 with 1.5 ​T external magnets. A) Representative hematoxylin-eosin (HE) staining slices of major organs and tumors in each group (white arrow: inflammatory injury, yellow dotted line: tumor metastases in distant organs, scale bars ​= ​500 ​μm); B) body weight growth curves (n ​= ​5, mean ​± ​SD, one-way ANOVA); C–F) plasma levels of C) alanine aminotransferase (ALT); D) aspartate aminotransferase (AST); E) blood urea nitrogen (BUN); F) creatinine (CR) in each group (n ​= ​3, mean ​± ​SD, one-way ANOVA, n.s.: no significance, ∗∗∗∗P ​< ​0.0001). (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)